SH-748 is under clinical development by Nanjing Sanhome Pharmaceutical and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase II drugs for Marginal Zone B-cell Lymphoma have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SH-748’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SH-748 is under development for the treatment of relapsed or refractory Peripheral T Cell Lymphomas including peripheral T-cell lymphoma unspecified(PTCL-U), angioimmunoblastic T-cell lymphoma(AITL), ALK+/ALK-anaplastic large cell lymphoma(ALCL), subcutaneous panniculitis-like T-cell lymphoma(SPTL), hematological tumors such as relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma, marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma and extranodal marginal zone B-cell lymphoma and splenic marginal zone B-cell lymphoma. The drug candidate is administered through oral route as a tablet. It acts by targeting phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit delta (PIK3delta).
For a complete picture of SH-748’s drug-specific PTSR and LoA scores, buy the report here.